Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

In an in­ter­view Fri­day, Rev­o­lu­tion Med­i­cines CEO Mark Gold­smith, who says he prefers to un­der­state rather than ex­ag­ger­ate, float­ed a lofty goal: cure pan­cre­at­ic can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER